Meng X, Ao L, Brown J M, Meldrum D R, Sheridan B C, Cain B S, Banerjee A, Harken A H
Department of Surgery, University of Colorado Health Sciences Center, Denver 80262, USA.
Am J Physiol. 1997 Oct;273(4):H1894-902. doi: 10.1152/ajpheart.1997.273.4.H1894.
Lipopolysaccharide (LPS) and tumor necrosis factor (TNF)-alpha independently induce cardioprotection against ischemia in the rat at 24 h after administration, suggesting that endogenously synthesized TNF-alpha may play a role in LPS-induced protection. The purposes of this study were 1) to delineate the time course of LPS-induced cardiac functional protection against ischemia and its relation with myocardial and circulating TNF-alpha profile, 2) to examine whether prior protein synthesis inhibition abrogates the protection, and 3) to assess the effects of TNF-alpha inhibition and neutralization on the protection. Rats were treated with LPS (0.5 mg/kg i.p.). Cardiac functional resistance to normothermic global ischemia-reperfusion was examined at sequential time points after LPS treatment in isolated hearts by the Langendorff technique. Myocardial and circulating TNF-alpha was determined by enzyme-linked immunosorbent assay at 1-24 h after LPS treatment. Protection was apparent at 24 h, 3 days, and 7 days but not at 2 or 12 h. Maximal protection at 3 days was abolished by cycloheximide pretreatment (0.5 mg/kg i.p. 3 h before LPS treatment). Increases in myocardial and circulating TNF-alpha preceded the acquisition of protection. Dexamethasone pretreatment (4.0 or 8.0 mg/kg i.p. 30 min before LPS treatment) abolished peak increase in myocardial TNF-alpha and substantially suppressed circulating TNF-alpha (54.3 and 85.9% inhibition, respectively) without an influence on the maximal protection. Similarly, maximal protection was not affected by TNF binding protein (40 or 80 microg/kg i.v. immediately after LPS treatment). The results suggest that LPS-induced cardiac functional protection against ischemia is a delayed and long-lasting protective response that may involve de novo protein synthesis. Although LPS-induced increase in myocardial and circulating TNF-alpha precedes the delayed protection, it may not be required for the delayed protection.
脂多糖(LPS)和肿瘤坏死因子(TNF)-α在给药后24小时可独立诱导大鼠心脏对缺血产生保护作用,这表明内源性合成的TNF-α可能在LPS诱导的保护作用中发挥作用。本研究的目的是:1)描绘LPS诱导的心脏功能对缺血的保护作用的时间进程及其与心肌和循环中TNF-α水平的关系;2)研究预先抑制蛋白质合成是否会消除这种保护作用;3)评估抑制和中和TNF-α对该保护作用的影响。给大鼠腹腔注射LPS(0.5mg/kg)。通过Langendorff技术在LPS处理后的不同时间点,对离体心脏进行常温全心缺血-再灌注实验,检测心脏功能对缺血的抵抗能力。在LPS处理后1-24小时,通过酶联免疫吸附测定法测定心肌和循环中的TNF-α水平。在24小时、3天和7天时出现明显的保护作用,但在2小时或12小时时未出现。环己酰亚胺预处理(在LPS处理前3小时腹腔注射0.5mg/kg)可消除3天时的最大保护作用。心肌和循环中TNF-α的增加先于保护作用的出现。地塞米松预处理(在LPS处理前30分钟腹腔注射4.0或8.0mg/kg)可消除心肌TNF-α的峰值增加,并显著抑制循环中的TNF-α(分别抑制54.3%和85.9%),但不影响最大保护作用。同样,TNF结合蛋白(在LPS处理后立即静脉注射40或80μg/kg)对最大保护作用也无影响。结果表明,LPS诱导的心脏功能对缺血的保护作用是一种延迟且持久的保护反应,可能涉及从头合成蛋白质。虽然LPS诱导的心肌和循环中TNF-α的增加先于延迟保护作用,但延迟保护作用可能并不需要它。